Mutual of America Capital Management LLC Has $3.46 Million Position in Roivant Sciences Ltd. (NASDAQ:ROIV)

Mutual of America Capital Management LLC raised its holdings in Roivant Sciences Ltd. (NASDAQ:ROIV) by 0.4% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 327,079 shares of the company’s stock after buying an additional 1,142 shares during the period. Mutual of America Capital Management LLC’s holdings in Roivant Sciences were worth $3,457,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. Rubric Capital Management LP grew its position in shares of Roivant Sciences by 81.0% in the 4th quarter. Rubric Capital Management LP now owns 19,000,000 shares of the company’s stock valued at $213,370,000 after acquiring an additional 8,500,000 shares during the period. Vanguard Group Inc. grew its position in shares of Roivant Sciences by 14.6% in the 1st quarter. Vanguard Group Inc. now owns 8,106,332 shares of the company’s stock valued at $85,441,000 after acquiring an additional 1,030,681 shares during the period. Norges Bank bought a new position in shares of Roivant Sciences in the 4th quarter valued at about $41,506,000. First Trust Advisors LP grew its position in shares of Roivant Sciences by 434.8% in the 4th quarter. First Trust Advisors LP now owns 2,739,438 shares of the company’s stock valued at $30,764,000 after acquiring an additional 2,227,192 shares during the period. Finally, Bank of New York Mellon Corp grew its position in shares of Roivant Sciences by 2.2% in the 2nd quarter. Bank of New York Mellon Corp now owns 2,686,538 shares of the company’s stock valued at $28,397,000 after acquiring an additional 58,541 shares during the period. 64.76% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

ROIV has been the subject of a number of analyst reports. Cantor Fitzgerald reissued an “overweight” rating on shares of Roivant Sciences in a research report on Thursday, September 19th. HC Wainwright reaffirmed a “buy” rating and set a $18.00 target price on shares of Roivant Sciences in a report on Thursday, September 19th. Piper Sandler lifted their target price on shares of Roivant Sciences from $20.00 to $22.00 and gave the stock an “overweight” rating in a report on Wednesday, July 10th. Finally, Bank of America lifted their target price on shares of Roivant Sciences from $12.00 to $12.50 and gave the stock a “neutral” rating in a report on Wednesday, September 11th. One equities research analyst has rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $17.39.

Roivant Sciences Stock Performance

NASDAQ ROIV opened at $11.90 on Tuesday. The company has a quick ratio of 27.91, a current ratio of 27.91 and a debt-to-equity ratio of 0.05. The company has a market capitalization of $8.79 billion, a P/E ratio of 2.35 and a beta of 1.25. Roivant Sciences Ltd. has a 12-month low of $8.24 and a 12-month high of $13.24. The firm has a 50-day moving average price of $11.47 and a two-hundred day moving average price of $11.06.

Roivant Sciences (NASDAQ:ROIV) last issued its earnings results on Thursday, August 8th. The company reported $0.12 EPS for the quarter, beating the consensus estimate of ($0.21) by $0.33. The company had revenue of $55.10 million during the quarter, compared to analysts’ expectations of $30.72 million. Roivant Sciences had a net margin of 2,991.75% and a negative return on equity of 17.23%. The business’s revenue for the quarter was up 155.1% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.38) EPS. Analysts anticipate that Roivant Sciences Ltd. will post -1.14 earnings per share for the current year.

Roivant Sciences Company Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.